The ORR for vibostolimab monotherapy was more significant than for combination therapy in the sub-cohort of NSCLC patients with anti–PD-1–PD-L1–refractory disease (7% (95% CI, 2%-20%) vs. 5% (95% CI, <1%-18%)) (206). Here, CD274 is linked to non-small cell lung carcinoma.